April 23rd 2024
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 Miami International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Monoclonal Antibody May Increase Survival Rate in Patients With Colorectal Cancer
September 1st 1998In patients with Dukes’ C colorectal cancer, therapy with a novel murine monoclonal antibody, Mab 17-1A (edrecolomab [Panorex]), manufactured by Centocor, reduced death by 32% and recurrence of disease by more than 23%, according to a
Radiolabeled Peptide Offers New Diagnostic Tool for Colorectal Cancer
September 1st 1998TORONTO--Visualization of gastrointestinal carcinomas is enhanced with the use of a radiolabeled peptide developed at the University of Vienna, according to a study presented at the 45th Annual Meeting of the Society of Nuclear Medicine (SNM).
Photography of the Cecum Should Accompany Colonoscopy, Say Researchers
July 1st 1998The best deterrent against colorectal cancer may be to photograph the cecum--where a significance incidence of colorectal cancer occurs--as a complement to performing colonoscopy, according to a study conducted in Allentown, Pennsylvania. The
Genetic Markers May Predict Risk for Lung, Prostate, Colorectal, and Cervical Cancers
June 1st 1998Recent advances in research focused on identifying genetic and other markers that can predict cancer risk were reported at the annual meeting of the American Association for Cancer Research (AACR). Included in the presentations were reports of
Rectal Cancer Said to Require Extensive Preop Evaluation
May 1st 1998COLUMBUS, Ohio--Rectal cancer is treated with a wide variety of operations and adjuvant therapy. This variety makes extensive preoperative evaluation mandatory, said Karamjit Khanduja, MD, chief of the Division of Colon and Rectal Surgery, Mt. Carmel Health, Columbus, Oho.
Virtual Colonoscopy a ‘Kinder, Gentler’ Colon Exam
April 1st 1998COLUMBUS, Ohio--Although virtual colonoscopy is a new and still evolving technology, it could one day prove to be more convenient and less expensive than traditional methods of colon cancer screening, said David J. Vining, MD, assistant professor of diagnostic radiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
APC Gene Mutation May Not Lead To Increased Colon Cancer Risk in Ashkenazi Jews
January 1st 1998A genetic mutation in the adenomatous polyposis (APC) gene found in 7% of Ashkenazi Jewish families in the United States does not necessarily lead to colon cancer, according to a study in the December 15, 1997, issue of Cancer Research.
Colorectal Cancer Surgical Practice Guidelines
July 1st 1997The Society of Surgical Oncology surgical practice guidelines focus on the signs and symptoms of primary cancer, timely evaluation of the symptomatic patient, appropriate preoperative evaluation for extent of disease, and role of the surgeon in
Colorectal Cancer Screening Is Cost-Effective, OTA Study Shows
May 1st 1996Screening for colon colon by any of several different strategies is highly cost effective, but nonetheless expensive. It is unclear whether American society--in the form of the federal government, private insurers, managed care organizations, or individual
Commentary (Nag): High-Dose-Rate Intraoperative Radiation Therapy For Colorectal Cancer
July 1st 1995In this issue, Harrison et al give the rationale for intraoperative high-dose-rate brachytherapy (IOHDR) and provide an excellent summary of the Memorial Sloan-Kettering Cancer Center (MSKCC) experience with this treatment. Intraoperative high-dose-rate brachytherapy is used in very few centers [1-4], and its worldwide use has been recently summarized [5,6]. Although our experience with IOHDR at Ohio State University parallels that of Harrison et al in some respects, it differs in others. I will highlight these differences to give readers a more balanced view of IOHDR.
High-Dose-Rate Intraoperative Radiation Therapy For Colorectal Cancer
July 1st 1995Intraoperative radiation therapy (IORT) has the obvious advantage of maximally irradiating the tumor bed while eliminating surrounding normal organs from the field of radiation. This approach has been especially useful when the required radiation dose exceeds the tolerance dose of the surrounding normal tissues. However, the application of IORT has been significantly limited by cost, logistic issues, and technical problems related to delivering treatment to difficult anatomic areas. We have developed a new approach to IORT that obviates the need for patient transport: In a dedicated, shielded operating room, the surgery is performed and IORT is delivered via HDR remote afterloading. We have found this approach to be cost effective, logistically sound, and suitable for a wide range of anatomic sites. The technical aspects of the procedure, as well our preliminary results in colorectal cancer, will be presented. Lastly, the authors present the technical aspects of delivering HDR intraoperative brachytherapy, their dosimetry atlas, and their results using HDR-IORT in the treatment of patients with colorectal cancer[ONCOLOGY 9(7):679-683, 1995]